Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Unternehmen & Branche
| Name | UroGen Pharma Ltd. |
|---|---|
| Ticker | URGN |
| CIK | 0001668243 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,14 Mrd. USD |
| Beta | 1,44 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 109,788,000 | -153,494,000 | 200,455,000 | -105,474,000 | |
| 2025-09-30 | 10-Q | 27,482,000 | -33,347,000 | 185,046,000 | -115,408,000 | |
| 2025-06-30 | 10-Q | 24,215,000 | -49,940,000 | 208,717,000 | -93,376,000 | |
| 2025-03-31 | 10-Q | 20,254,000 | -43,843,000 | 247,618,000 | -46,458,000 | |
| 2024-12-31 | 10-K | 24,565,000 | -37,512,000 | 285,711,000 | -8,803,000 | |
| 2024-09-30 | 10-K | 25,204,000 | -23,673,000 | |||
| 2024-09-30 | 10-Q | 25,204,000 | -23,673,000 | 301,943,000 | 25,515,000 | |
| 2024-06-30 | 10-K | 21,848,000 | -33,403,000 | |||
| 2024-06-30 | 10-Q | 21,848,000 | -33,403,000 | 281,849,000 | 30,314,000 | |
| 2024-03-31 | 10-K | 18,781,000 | -32,286,000 | |||
| 2024-03-31 | 10-Q | 18,781,000 | -32,286,000 | 200,574,000 | -40,134,000 | |
| 2023-12-31 | 10-K | 23,530,000 | -26,016,000 | 178,311,000 | -65,212,000 | |
| 2023-09-30 | 10-K | 20,852,000 | -21,879,000 | |||
| 2023-09-30 | 10-Q | 20,852,000 | -21,879,000 | 193,633,000 | -41,993,000 | |
| 2023-06-30 | 10-K | 21,139,000 | -24,136,000 | |||
| 2023-06-30 | 10-Q | 21,139,000 | -24,136,000 | 95,361,000 | -138,434,000 | |
| 2023-03-31 | 10-K | 17,192,000 | -30,213,000 | |||
| 2023-03-31 | 10-Q | 17,192,000 | -30,213,000 | 112,954,000 | -116,554,000 | |
| 2022-12-31 | 10-K | 64,357,000 | -109,783,000 | 135,619,000 | -89,361,000 | |
| 2022-09-30 | 10-Q | 16,097,000 | -25,831,000 | 128,473,000 | -63,286,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.